Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C trial).
O’Brien T, Ray E, Singh R et al.; British Association of Urological Surgeons Section of Oncology.
After a nephroureterectomy, up to 40% of patients will develop bladder cancer. Approximately 70% of cases who develop cancer following nephroureterectomy do so within the first year following surgery.